Reuters logo
BRIEF-Zai Lab announces dosing of first patient in late-stage, ovarian cancer trial
September 29, 2017 / 12:13 PM / 2 months ago

BRIEF-Zai Lab announces dosing of first patient in late-stage, ovarian cancer trial

Sept 29 (Reuters) - Zai Lab Ltd

* Zai Lab Limited announces dosing of first patient in Phase 3 registration trial of ZL-2306 (niraparib) for treatment of ovarian cancer

* Zai Lab - evaluating niraparib in prima trial, Phase 3 clinical trial in first-line maintenance setting in platinum-responsive ovarian cancer patients​

* Zai Lab Ltd says plans to initiate the trial in first half of 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below